 Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has successfully concluded a meeting with the Scientific Advice Working Party SAWP of the European Medicines Agency EMA regarding Phase III development of its drug candidate Namodenoson in the treatment of hepatocellular carcinoma HCC, the most common form of liver cancer. 